Acute Epiglottitis in the Immunocompromised Host: Case Report and Review of the Literature

Cheng Chen,1 Mukil Natarajan,2 David Bianchi,3 Georg Aue,4 and John H. Powers5

1University of Cambridge, Cambridge, United Kingdom; 2Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; 3National Institute on Deafness and Communication Disorders, National Institutes of Health, Bethesda, Maryland; 4Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; 5Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, Maryland

We present a case of acute epiglottitis in a 16-year-old with severe aplastic anemia. He was admitted with a history suggestive of a severe upper airway infection and an absolute neutrophil count of 0 per cubic millimeter. Despite his immunocompromised state, he presented with the classical signs and symptoms of epiglottitis. We review here the presentation and comorbidities of immunocompromised patients with epiglottitis. In addition, the appropriate choice of empirical antibiotic therapy is important for the management of epiglottitis in immunocompromised patients, especially in the post–Haemophilus influenza type B vaccination era. In our patient, Enterobacter cloacae was isolated from endoscopically directed throat cultures, and treatment was successful without the need for intubation. The current literature suggests that in immunocompromised patients, particularly those who are neutropenic, there is a potentially wide range of organisms, both bacterial and fungal, that may play a role in the pathology of acute epiglottitis.

Keywords. aplastic anemia; Enterobacter cloacae; epiglottitis; immunocompromise; malignancy; neutropenia.

Epiglottitis is a life-threatening condition, characterized by acute inflammation of the supraglottic region of the oropharynx, with the potential risk of fatal airway obstruction. Effective management requires rapid diagnosis, airway management, and treatment of the causative agent. Epiglottitis is an inflammatory disease, yet it still occurs in patients whose inflammatory responses are blunted by neutropenia and immunocompromised patients. Although these patients are known to be more susceptible to infections, it has yet to be demonstrated whether epiglottitis in immunocompromised patients presents differently or follows a different clinical course. Previously, 75%–90% of cases of epiglottitis were caused by Haemophilus influenza type B (Hib). Vaccination, introduced in 1985, significantly reduced the incidence of epiglottitis [1]. Cases presenting today show a mixed microbial etiology, with a relative increased incidence in older children [2]. Epiglottitis in immunocompromised patients may be caused by a wider variety of organisms than epiglottitis in immunocompetent children and adolescents. We present here a case of acute epiglottitis with Enterobacter cloacae in a 16-year-old male with severe aplastic anemia with a review of the literature, exploring the clinical presentation, outcomes, and microbial etiologies in immunocompromised patients.

CASE REPORT

A 16-year-old Jamaican male presented to his local hospital with fatigue, epistaxis, and dyspnea. He had no significant past medical history or family history of serious medical illness. Initial blood tests showed a white cell count of 1900 per cubic millimeter (absolute neutrophil count 90 per cubic millimeter), hemoglobin 5.3 g per deciliter, and platelets 36 000 per cubic millimeter. He was hospitalized 3 months later, and bone marrow biopsy performed 1 month into the admission was consistent with aplastic anemia. He was discharged after receiving packed red blood cells, pooled platelet transfusions, and intravenous antibiotics of unknown type, dose, and duration.

Five months after initial presentation, he was admitted to the US National Institute of Health Clinical Center with a 1-week history of fever, dysphagia, odynophagia, cough, and scant hemoptysis. He was enrolled in an institutional review board–approved clinical research protocol, and informed consent was obtained and documented. On examination, his body temperature was 38.2°C, blood pressure 126/91 mm Hg, heart rate 88 beats per minute, respiratory rate 18 breaths per minute, and oxygen saturation 98% breathing ambient room air. He appeared thin and lethargic, but was not in acute distress, and was spitting blood-tinged saliva into a cup. He denied dyspnea and was phonating normally. He was tender diffusely around
the neck. There were no other abnormal examination findings. His laboratory findings showed a white cell count of 1430 per cubic millimeter (absolute neutrophil count 0 per cubic millimeter), hemoglobin 10.7 g per deciliter, and platelets 33 000 per cubic millimeter. Radiographic imaging showed a classic “thumbprint” sign at the site of the epiglottis (Figure 1). Direct laryngoscopy showed an erythematous, enlarged, and posteriorly ptotic epiglottis that was not necrotic (Figure 2). The patient immediately received intravenous piperacillin/tazobactam (3.375 g, every 6 hours), vancomycin (400 mg, every 6 hours), and micafungin (100 mg, once daily), as well as intravenous dexamethasone (4 mg, every 6 hours) and nebulized racemic epinephrine (0.5 mL of 2.25%, every 6 hours). He clinically improved while being closely monitored in the intensive care unit; there was no need for definitive airway management by intubation. Blood cultures showed no growth, but endoscopically directed cultures from directly observed exudate on the right tonsillar area isolated Enterobacter cloacae resistant to cefazolin, cefoxitin, ceftazidime, ceftriaxone, co-amoxiclav, ampicillin, aztreonam, and piperacillin/tazobactam; subsequently, he was prescribed meropenem (750 mg, every 8 hours). He clinically improved with this antibiotic regimen, and follow-up laryngoscopy 17 days later showed significant improvement in the appearance of the epiglottis (Figure 3).

**DISCUSSION**

Epiglottitis is a medical emergency, with the potential serious complication of airway compromise secondary to the inflammatory response to infection in the upper airway. It is a clinical diagnosis characterized by odynophagia, stridor, drooling, and a “hot potato” voice. The patient may also show signs of sepsis in cases of severe infection. Direct fibreoptic laryngoscopy shows an inflamed and swollen epiglottis; however, examination should be done with caution as it can lead to rapid airway compromise. Radiology, including lateral x-ray of the cervical spine or computerized tomography, may aid in diagnosis by showing a classic “thumbprint sign,” evidence of soft tissue swelling of the epiglottis. While antimicrobials are part of treatment, additional support, including steroids [3], is used to reduce the inflammation, and intubation/tracheostomy under carefully monitored conditions maintains the collapsing airway. In cases where there is abscess formation, surgical debridement may also be necessary. Isolated necrosis of the epiglottis also can occur [29].

**Demographics of Epiglottitis in the Immunocompromised**

We performed a literature search evaluating epiglottitis in the immunocompromised host, which yielded 48 published cases from 34 published reports (Table 1) [4–37]. Patient ages ranged from 4 months to 70 years, with a mean age of 35.5 years, with 23 male and 25 female patients. Twenty-four had immunocompromise secondary to cancer and/or chemotherapy, and 12 patients were positive for HIV. The remainder had a variety of causes of immunocompromise, including Epstein-Barr virus (EBV) mononucleosis, renal transplantation, and drug-induced
neutropenia (see the footnote to Table 1). Of these 48 patients, 18 were neutropenic, defined by an absolute neutrophil count and/or total white cell count of less than 1000 per cubic millimeter. The range of underlying causes of immunocompromise in neutropenic patients was similar to that in non-neutropenics.

Clinical Presentation of Epiglottitis in the Immunocompromised

Epiglottitis has previously been reported in 1 other patient with aplastic anemia [12]. Our patient presented with typical signs and symptoms of epiglottitis similar to those observed in immunocompetent patients. Specifically, in the reviewed case reports of immunocompromised patients, patients presented with symptoms of respiratory distress, stridor, fever, drooling, sore throat, odynophagia, and dysphagia [4–37].

In our patient, there was no stridor or pus on laryngoscopy. Neutrophils are the key effector cells of the innate immune system, so when patients become neutropenic (<500 per cubic millimeter), they become susceptible to infections. Sore throat due to mucositis may be common in patients receiving chemotherapy for malignancy, but there should be a high index of suspicion if symptoms worsen or progress to include difficulty swallowing, clearing secretions, or breathing. We postulate that there are 3 reasons why, despite the ongoing inflammation and medical intervention, this patient's airway remained competent without any need for airway support. First is that, anatomic-ally, this 16-year-old's head and neck anatomy may be different compared with younger children with H. influenzae epiglottitis. There is more space for the swelling to expand before impinging on the airway. Second, there is an inverse correlation between patient age and risk of laryngospasm [38]. Third, the severity of his immunocompromise from aplastic anemia may have limited the extent of host response, thereby presenting a lower-than-expected degree of inflammation and swelling.

Clinical Course, Treatment, and Outcomes of Epiglottitis in the Immunocompromised

The majority of cases were empirically treated initially with broad-spectrum antibiotics. Of the 21 patients in whom fungal organisms were isolated, 7 empirically received antifungal agents, including 2 patients with concomitant neutropenia. As many of the organisms isolated are part of the normal oropharyngeal flora, especially *Candida* sp, their role in infection vs colonization often is unclear. The benefits or harms of administering antifungals empirically are unclear from this case series.

Prognosis of Epiglottitis in the Immunocompromised

Of the 48 case reports, 13 people died and 35 survived (27% overall mortality), highlighting the life-threatening nature of epiglottitis. Of the neutropenic patients, 6 died and 12 survived, giving a slightly higher mortality of 33% (Table 1). Two of 3 patients with tongue involvement were neutropenic.

Table 1. Demographics of Epiglottitis in the Immunocompromised According to 48 Cases from Published Studies [4–37]

| Demographic | Data for Cases |
|-------------|----------------|
| Mean age (SD, range), y | 35.5 (20.1, 4 mo–70 y) |
| Sex         | Male 23 48% |
|             | Female 25 52% |
| Underlying condition | Malignancy 24 50% |
|             | HIV 12 25% |
|             | Other 12 25% |
| Neutropenia | ANC or WBC <1000 18 38% |
| Mortality   | Neutropenic 33% |
|             | Not neutropenic 23% |

Abbreviations: ANC, absolute neutrophil count; WBC, total white blood cell count.

*Other causes of immunocompromise included Epstein-Barr virus (EBV) mononucleosis in pregnancy, bone marrow aplasia of unknown origin, hypoplastic bone marrow of unknown origin, aplastic anemia, virus-associated hemophagocytic syndrome secondary to EBV infection, renal transplantation, procainamide-induced neutropenia, infection-related hemophagocytic lymphohistiocytosis, Cytomegalovirus-related pancytopenia, systemic lupus erythematosus, and drug-induced agranulocytosis. In 1 patient, the cause of immunocompromise was not documented.

In our patient, there was no stridor or pus on laryngoscopy. Neutrophils are the key effector cells of the innate immune system, so when patients become neutropenic (<500 per cubic millimeter), they become susceptible to infections. Sore throat due to mucositis may be common in patients receiving chemotherapy for malignancy, but there should be a high index of suspicion if symptoms worsen or progress to include difficulty swallowing, clearing secretions, or breathing. We postulate that there are 3 reasons why, despite the ongoing inflammation and medical intervention, this patient's airway remained competent without any need for airway support. First is that, anatomic-ally, this 16-year-old's head and neck anatomy may be different compared with younger children with H. influenzae epiglottitis. There is more space for the swelling to expand before impinging on the airway. Second, there is an inverse correlation between patient age and risk of laryngospasm [38]. Third, the severity of his immunocompromise from aplastic anemia may have limited the extent of host response, thereby presenting a lower-than-expected degree of inflammation and swelling.

Clinical Course, Treatment, and Outcomes of Epiglottitis in the Immunocompromised

The majority of cases were empirically treated initially with broad-spectrum antibiotics. Of the 21 patients in whom fungal organisms were isolated, 7 empirically received antifungal agents, including 2 patients with concomitant neutropenia. As many of the organisms isolated are part of the normal oropharyngeal flora, especially *Candida* sp, their role in infection vs colonization often is unclear. The benefits or harms of administering antifungals empirically are unclear from this case series.

Prognosis of Epiglottitis in the Immunocompromised

Of the 48 case reports, 13 people died and 35 survived (27% overall mortality), highlighting the life-threatening nature of epiglottitis. Of the neutropenic patients, 6 died and 12 survived, giving a slightly higher mortality of 33% (Table 1). Two of 3 patients with tongue involvement were neutropenic.

Table 1 shows the interventions used in addition to antimicrobial agents and their associated mortalities in the patients who received them.

It is not possible to determine the effects of various interventions on mortality from this case series. Intubation and tracheostomy may be used in more severe cases, so higher mortality with these interventions may reflect higher baseline risk of death independent of the interventions administered.

Organisms Isolated in Immunocompromised Patients

In 29 patients, a single organism was isolated from cultures of the throat, sputum, blood, or tissue biopsy (either from an isolated site or from multiple sites), while 3 patients had either no growth on cultures or they were not done. The remaining 16 patients grew multiple organisms. A summary of organisms is shown in Table 3. The most frequent organism isolated from either cultures or biopsy was *Candida* spp, followed by *Streptococcus* spp.
Eight of the neutropenic patients grew *Candida* spp and were subsequently treated with antifungal agents (11 of 31 non-neutropenic patients grew *Candida* spp). The organisms grown from neutropenic patients showed more variety and were less predictable, such as *Prevotella* spp and *Serratia marcescens*, compared with primarily *Streptococcus pneumoniae* and *Candida albicans* in non-neutropenic patients. In 2 patients, cultures were not done, diagnosis was made on a clinical basis, and the infection resolved without intervention. There was 1 case where there was no growth from blood cultures, throat swabs, or tracheal aspirate, but the patient survived and the disease resolved after receipt of cefotaxime, erythromycin, and metronidazole.

Here we report the first documented case of acute epiglottitis associated with *Enterobacter cloacae*, a gram-negative rod-shaped organism often found in the normal flora of the gastrointestinal tract [39]. It is also a nosocomial pathogen, with previous documentation of *E. cloacae* outbreaks [40]. Flynn et al. suggested that *Enterobacter* from patients’ endogenous flora can be the source of “nosocomial” *Enterobacter* infection [41]. Our patient did recently have a hospital admission in Jamaica and receipt of prior antibiotics, so it is unclear whether the source of his infection was nosocomial or community acquired. Nonetheless, this finding has implications for the choice of empirical antimicrobial therapy for the initial management of epiglottitis in immunocompromised patients. Gram-negative and fungal infections should be considered in this setting.

**CONCLUSIONS**

In the immunocompromised patient, there should be a low threshold of suspicion for diagnosing acute epiglottitis, particularly in those who are neutropenic. The immunocompromised state and neutropenia do not rule out diseases caused by neutrophilic infiltration as tissue-based inflammation still may result in disease. Epiglottitis in reported cases presents similarly in immunocompromised and immunocompetent patients. Early recognition can allow prompt treatment, including administration of broad-spectrum antimicrobials and perhaps antifungals, given the wide range of organisms isolated. The impact of broad-spectrum antimicrobials with additional antifungals on outcome is unknown given that the organisms isolated also are part of the normal oropharyngeal flora, and whether they are colonizing or causing infection often is unclear. Airway management is paramount, but endotracheal intubation is not always necessary and was not necessary in our patient. Sedation, inhalers, and racemic epinephrine should be avoided [3]. Rapid treatment with steroids to reduce the immediate inflammation, along with antimicrobials to treat the underlying infection, has been associated with shorter intensive care unit and overall length of hospital stay; close monitoring and good nursing care are essential for the appropriate management of epiglottitis in the immunocompromised patient.

**Acknowledgments**

Financial support. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Potential conflicts of interest. None of the authors have any conflict of interest related to this work. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Shah RK, Stocks C. Epiglottitis in the United States: national trends, variances, prognosis, and management. Laryngoscope 2010; 120:1256–62.
2. Senior BA, Radkowski D, MacArthur C, et al. Changing patterns in pediatric supraglottitis: a multi-institutional review, 1980 to 1992. Laryngoscope 1994; 104:1314–22.
3. Guardiani E, Bliss M, Harley E. Supraglottitis in the era following widespread immunization against Haemophilus influenzae type B: evolving principles in diagnosis and management. Laryngoscope 2010; 120:2183–8.
4. Balsam D, Sorrano D, Baraz C. Candida epiglottitis presenting as stridor in a child with HIV infection. Pediatr Radiol 1992; 22:235–6.
5. Biem J, Roy L, Halik J, Hofstein V. Infectious mononucleosis complicated by necrotizing epiglottitis, dysphagia, and pneumonia. Chest 1989; 96:204–5.
6. Bolivar R, Gomez LG, Luna M, et al. Aspergillus epiglottitis. Cancer 1983; 51:367–70.
7. Bower CM, Suen JY. Adult acute epiglottitis caused by Enterobacter cloacae. Cancer 1987; 65:78–80.
8. Chemaly RF, Fox SB, Alkotob LM, et al. A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient. Scand J Infect Dis 2002; 34:149–51.
9. Chiou CC, Seibel NL, Derito FA, et al. Concomitant Candida epiglottitis and disseminated Varicella zoster virus infection associated with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2006; 28:757–9.
10. Cochran JH, Fee WE, Maze A. Epiglottitis in an immunocompromised host. West J Med 1979; 131:150–2.
11. Cole S, Zawin M, Lundberg B, et al. Candida epiglottitis in an adult with acute nonlymphocytic leukemia. Am J Med 1987; 82:662–4.
12. Colman MF. Epiglottitis in immunocompromised patients. Head Neck Surg 1986; 8:466–8.
13. Connolly AA, Rowe-Jones J, Leighton SE, et al. Pseudomonal supraglottitis occurring in a patient with profound neutropenia secondary to virus-associated hemophagocytic syndrome. J Laryngol Otol 1991; 106:739–40.
14. Cullis JO, Hyde RD. Acute epiglottitis in immunocompromised patients—a report of two cases. Clin Lab Haematol 1991; 13:379–82.
15. Eckmann DM, Selgman I, Coté CJ, Huwong JW. Mucormycosis supraglottitis on induction of anesthesia in an immunocompromised host. Anesth Analg 1998; 86:729–30.
16. French PD, Birchall MA, Harris JR. Cytomegalovirus ulceration of the oropharynx. J Laryngol Otol 1991; 105:739–42.
17. Goldsmith AJ, Schaeffer BT. Necrotizing epiglottitis in a patient with procainamide-induced neutropenia. Am J Otolaryngol 1994; 15:58–62.
18. Gorfinkel HJ, Brown R, Kabins SA. Acute infectious epiglottitis in adults. Ann Intern Med 1969; 70:289–94.
19. Hass A, Hyatt AC, Kattan M, et al. Hoarseness in immunocompromised children: association with invasive fungal infection. J Pediatr 1987; 111:731–3.
20. Israel L, Sadigh M. Candida epiglottitis in an adult with acquired immunodeficiency syndrome treated with oral fluconazole. J Laryngol Otol 1995; 109:337–9.
21. Kennedy CA, Rosen H. Kingella kingae bacteremia and adult epiglottitis in a granulocytopenic host. Am J Med 1988; 85:701–2.
22. Kessler HA, Schade R, Trenholme GM, et al. Acute pneumococcal epiglottitis in immunocompromised adults. Scand J Infect Dis 1980; 12:207–10.
23. Kong MS, Engel SH, Zalalz GH, Preciado D. Necrotizing epiglottitis and hemophagocytic lymphohistiocytosis. Int J Pediatr Otorhinolaryngol 2009; 73:119–25.
24. Lake JA, Ehrhardt MJ, Suchi M, et al. A case of necrotizing epiglottitis due to nontoxicogenic Corynebacterium diptheriae. Pediatrics 2015; 136:e242–5.
25. Lederman MM, Lowder J, Lerner PL. Bacteremic pneumococcal epiglottitis in adults with malignancy. Am Rev Respir Dis 1982; 125:117–8.
26. Mannekar G, Chitranshi PB, Ghosh S. Acute epiglottitis in an adult leukemia patient. World Art Ear Nose Throat 2009; 2. Available at: http://www.waent.org/archives/2009/vol2-2/epiglottitis/epiglottitis.htm
27. Ohashi T, Mizuta K, Kuze B, et al. Invasive epiglottic aspergillosis: a case report and literature review. Auris Nasus Larynx 2015; 42:501–4.
28. Parment PA, Hagberg L. Fatal Serratia marcescens epiglottitis in a patient with leukaemia. J Infect 1987; 14:280.
29. Rothstein SG, Persky MS, Edelman BA, et al. Epiglottitis in AIDS patients. Laryngoscope 1989; 99:389–92.
30. Sengör A, Willke A, Aydin O, et al. Isolated necrotizing epiglottitis: report of a case in a neutropenic patient and review of the literature. Ann Otol Rhinol Laryngol 2004; 113:225–8.
31. Shalit M, Gross DJ, Levo Y. Pneumococcal epiglottitis in systemic lupus erythematosus on high-dose corticosteroids. Ann Rheum Dis 1982; 41:615–6.
32. Sharma N, Berman DM, Scott GB, Josephson G. Candida epiglottitis in an adolescent with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2005; 24:91–2.
33. Siegel RJ, Browning D, Schwartz DA, Hudgins PA. Cytomegaloviral laryngitis and probable malignant lymphoma of the larynx in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 1992; 116:539–41.
34. Srikanthabalan P, Roy RB. Aspergillus infection of the epiglottis in a HIV positive patient. Genitourin Med 1996; 72:431–2.
35. Tashjian LS, Peacock JE. Laryngeal candidiasis. Report of seven cases and review of the literature. Arch Otolaryngol 1984; 110:806–9.
36. Tebruegge M, Connell T, Kong K, et al. Necrotizing epiglottitis in an infant: an unusual first presentation of human immunodeficiency virus infection. Pediatr Infect Dis J 2009; 28:164–6.
37. Walsh TJ, Gray WC. Candida epiglottitis in immunocompromised patients. Chest 1987; 91:482–5.
38. Gavel G, Walker RWM. Laryngospasm in anaesthesia. Contin Educ Anaesth Crit Care Pain 2014; 14: 47–51.
39. Sommers HM. The indigenous micro biota of the human host. In: Youmans GP, Paterson PY, Sommers HM, eds. The Biologic and Clinical Basis of Infectious Disease and literature review. Auris Nasus Larynx 1982; 96:204–5.
40. Dalben M, Varkulja G, Basso M, et al. Investigation of an outbreak of Enterobacter cloacae in a neonatal unit and review of the literature. J Hosp Infect 2008; 70:7–14.
41. Flynn DM, Weinstein RA, Nathan C, et al. Patients’ endogenous flora as the source of “nosocomial” Enterobacter in cardiac surgery. J Infect Dis 1987; 156:363–8.